Exploring Biotech ETF Opportunities: A Strategic Guide to Five Emerging Sector Funds

When building an investment portfolio with exposure to the biotechnology sector, many investors turn to exchange-traded funds as a practical solution. Biotech ETFs offer a convenient way to gain diversified access to multiple companies within the industry through a single investment vehicle, reducing the risk associated with holding individual biotech stocks. This approach is particularly appealing for those who want sector exposure without concentrating their investment in one company. The following analysis examines five specialized biotech ETF options, with all figures and asset data current as of February 9, 2026, providing a snapshot of the sector’s smaller-cap fund opportunities.

Leveraged Biotech Strategies: Amplified Daily Returns

ProShares Ultra NASDAQ Biotechnology ETF (NASDAQ:BIB) represents the aggressive end of the biotech ETF spectrum. With assets under management of US$89.54 million, this fund, launched in April 2010, employs a 2x leverage mechanism designed to track twice the daily performance of the NASDAQ Biotechnology Index. This structure makes it suitable for investors maintaining a bullish near-term outlook on the biotech and pharmaceutical sectors.

However, the fund’s distinctive leverage mechanism carries important caveats. Investors with lower risk tolerance or those following a traditional buy-and-hold investment philosophy are advised against this strategy due to daily rebalancing effects and potential volatility amplification. Among its 263 holdings, the portfolio’s heaviest weightings include Gilead Sciences (NASDAQ:GILD) at 6.78 percent, Amgen (NASDAQ:AMGN) at 6.23 percent, and Vertex Pharmaceuticals (NASDAQ:VRTX) at 6.17 percent—positioning investors in some of the sector’s largest players while maintaining broader sector exposure.

Inverse Strategies: Shorting the Biotech Sector

Direxion Daily S&P Biotech Bear 3X Shares (ARCA:LABD) operates from the opposite end of the investment spectrum, providing three times the inverse daily return of the S&P Biotechnology Select Industry Index. This means the fund gains value when biotech equities decline and loses value when they rise—a distinct advantage for investors positioned for sector weakness or seeking hedge protection.

Leveraged inverse ETFs are fundamentally designed for short-term tactical trading rather than long-term portfolio building. The fund carries substantial risk due to amplified exposure to market volatility and daily compounding effects. Unlike traditional biotech ETFs that hold actual company shares, LABD achieves its investment objective through financial derivatives such as futures and swaps, creating a different risk-return profile that demands careful position monitoring. With US$68.18 million in assets, this fund serves a specialized niche within the biotech ETF landscape.

Specialized Therapeutic Focus: Disease-Specific Investing

Tema Heart and Health ETF (NASDAQ:HRTS) launched in November 2023 with a distinctly narrower mandate than broad-based biotech funds. This ETF zeroes in on companies developing treatments for diabetes, obesity, and cardiovascular diseases—therapeutic areas gaining significant market attention. The fund underwent multiple rebrandings (March 25 and June 27), reflecting the rapid evolution of investor interest in these disease categories.

Holding 46 biotech and pharmaceutical companies, HRTS maintains a composition of approximately 75 percent large-cap stocks and 22 percent mid-cap holdings, with about three-quarters based in the United States. This therapeutic specialization contrasts with broader biotech indices, allowing investors to make conviction bets on specific disease areas. Its top holdings include Eli Lilly and Company (NYSE:LLY) at 10.04 percent weight, Roche Holding (OTCQX:RHHBY, SWX:ROG) at 5.42 percent, and Johnson & Johnson (NYSE:JNJ) at 4.8 percent—all major players in the metabolic and cardiovascular spaces.

Genomics and Gene Technology: Frontier Biotech Focus

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) takes investors into the cutting-edge frontier of genetic science. With US$51.53 million under management, this fund tracks the Solactive Genomics Index and concentrates on companies engaged in gene editing, genomic sequencing, genetic medicine, computational genomics, and advanced biotech applications. This represents a more specialized position within the broader biotech universe.

The fund’s 50-stock portfolio maintains approximately 90 percent allocation to the pharmaceuticals, biotechnology, and life sciences sector, ensuring thematic purity. Its core holdings include Moderna (NASDAQ:MRNA) at 6.33 percent, Arrowhead Pharmaceuticals (NASDAQ:ARWR) at 6.14 percent, and Praxis Precision Medicines (NASDAQ:PRAX) at 5.98 percent—companies at the forefront of genetic innovation and RNA-based therapeutics.

FDA-Approved Products: Established Commercial Biotech

Virtus LifeSci Biotech Products ETF (ARCA:BBP) targets a distinctly different biotech investment thesis: proven commercial viability. Launched in December 2014, this fund tracks the LifeSci Biotechnology Products Index, focusing exclusively on US-listed biotech companies with at least one FDA-approved drug therapy already on the market. This screening mechanism ensures portfolio companies have cleared regulatory hurdles and generated actual revenue.

The fund’s US$44.8 million in assets are distributed across companies ranging from emerging growth firms to established players, using an equal-weighted rebalancing strategy adjusted semi-annually. This equal-weight approach differs from cap-weighted index funds, giving smaller FDA-approved biotech companies greater portfolio representation. Leading holdings include ImmunityBio (NASDAQ:IBRX) at 3.98 percent weight, Mirum Pharmaceuticals (NASDAQ:MIRM) at 2.4 percent, and Moderna at 2.16 percent—representing a mix of emerging and established biotech enterprises with approved therapeutics.

Strategic Considerations for Biotech ETF Selection

The five biotech ETF vehicles outlined above represent distinct investment philosophies and risk profiles. Leveraged funds like BIB suit aggressive traders with specific short-term convictions, while inverse strategies like LABD serve hedging and tactical short positioning. Disease-focused offerings like HRTS enable thematic bets on high-growth markets, genomics-focused strategies like GNOM target frontier technology, and product-stage funds like BBP emphasize commercial validation. Selecting the appropriate biotech ETF requires aligning fund characteristics with individual investment timeframe, risk tolerance, and sector conviction.